Admedus is a diversified healthcare company with activities that are focused on areas of medical need to help patients who currently suffer reduced outcomes that adversely affect their quality of life.

R&D – our lead investment in Professor Ian Frazer’s vaccine technology is targeting HSV2 and HPV and has both preventative and therapeutic properties that can be applied to a range of infectious diseases and cancers. Read more…
Commercialisation– the first product from our regenerative medicine division has recently been launched in Europe and is undergoing regulatory approval in key markets including the US. CardioCel®, a cardiovascular patch, is the first in a range of products that target soft tissue repair in the human body. Read more…
Sales and Distribution – expansion and growth by acquisition will enable the distribution arm of the company to expand from its Australian footprint as a global provider of our own and third party medical devices and consumables. View products…